Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference
January 07 2021 - 4:30PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, today announced that Keith Sullivan,
President and Chief Executive Officer, and Steve Furlong, Chief
Financial Officer, will be presenting at the 23rd Annual ICR
Westwicke Conference, and participating in a panel discussion on
Thursday, January 14, 2021.
23rd Annual ICR/Westwicke
Conference (Presentation & Panel Discussion)Thursday,
January 14, 2021 Presentation Time: 12:15pmPanel Name: Non-Drug
Therapeutics: Devices Changing the Treatment ParadigmPanel Time:
1:45 - 2:30pmA live audio webcast of the ICR Westwicke Conference
presentation will be available online at the investor relations
page of the Company’s website at ir.neuronetics.com. A replay of
the webcast will be archived on the website for approximately 90
days.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.Investor Contact:Mark R.
KlausnerWestwicke
Partners443-213-0501
ir@neuronetics.com Media
Contact:Chelsey MankoVault
Communications610-455-2778
cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Sep 2023 to Sep 2024